Navigation Links
InterMune Presents Research on ITMN-191 in Hepatitis C at EASL,Annual Meeting

CDC), an estimated 3.9 million Americans (1.8%) have been infected with HCV, of whom 2.7 million are chronically infected. It is estimated that there are 170 million people worldwide afflicted with this disease. While currently available therapies can cure many patients, there is considerable need for the development of novel therapeutic approaches. The HCV NS3/4 protease is an attractive drug target because of its potential involvement in viral replication and suppressive effects on host response to viral infection. Inhibitors of the HCV protease, such as ITMN-191, represent a promising new class of drugs for HCV.

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 in Phase 1a, a second-generation HCV protease inhibitor program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Except for the historical information contained herein, this press release contains certain forward-looking statements that involve risks and uncertainties, including without limitation the statements related to the progress, future patient enrollment in and timing of our clinical trials and announcements of results thereof. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof
'"/>




Page: 1 2 3 4

Related medicine technology :

1. InterMune Presents Research on ITMN-191 in Hepatitis C at Digestive Disease Week Meeting
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: InterMune Presents Research ITMN Hepatitis EASL Annual Meeting
(Date:9/19/2014)... Mich. , Sept. 19, 2014  Diplomat, the ... of David Dreyer to the Board of ... independent director and will also serve as chair of ... almost 30 years of accounting, financial, compliance and operating ... Mr. Dreyer has served as chief financial officer, chief ...
(Date:9/19/2014)... , Sept. 19, 2014 UBM Medica ... a leading online community to help oncologists and other ... available regarding the use of targeted therapies and immunotherapies, ... research and treatment.  Every September, ... way to raise awareness about blood cancers—helping to increase ...
(Date:9/19/2014)... 2014 Five MinuteClinic walk-in medical clinics are opening inside ... area. Three clinics opened in Memphis and ... will be added in Springfield on September ... is expected to open October 22.  MinuteClinic is the largest and ... United States . The Memphis ...
Breaking Medicine Technology:David Dreyer Appointed to Diplomat Board of Directors 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4MinuteClinic Walk-in Medical Clinics Opening in Memphis 2MinuteClinic Walk-in Medical Clinics Opening in Memphis 3
... , , , , , , , , , ... and LAUSANNE, Switzerland , February 4 ... Debiopharm Group (Debiopharm), a Swiss-based global,biopharmaceutical group of companies with ... medical needs, announce the launch by,Ipsen in France ...
... , REDWOOD CITY, Calif. , Feb. ... financial results for the year ended December 31, 2009 , which ... cash flow positive. , Total revenue for the fourth quarter of 2009 ... in the fourth quarter of 2008.  Product revenue from the Onco type ...
Cached Medicine Technology:Launch of Ipsen's Decapeptyl(R) 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer 2Launch of Ipsen's Decapeptyl(R) 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer 3Launch of Ipsen's Decapeptyl(R) 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer 4Launch of Ipsen's Decapeptyl(R) 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer 5Launch of Ipsen's Decapeptyl(R) 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer 6Genomic Health Announces Year-End 2009 Financial Results 2Genomic Health Announces Year-End 2009 Financial Results 3Genomic Health Announces Year-End 2009 Financial Results 4Genomic Health Announces Year-End 2009 Financial Results 5Genomic Health Announces Year-End 2009 Financial Results 6Genomic Health Announces Year-End 2009 Financial Results 7Genomic Health Announces Year-End 2009 Financial Results 8Genomic Health Announces Year-End 2009 Financial Results 9Genomic Health Announces Year-End 2009 Financial Results 10Genomic Health Announces Year-End 2009 Financial Results 11Genomic Health Announces Year-End 2009 Financial Results 12
(Date:9/19/2014)... September 19, 2014 Outsourcing services provider Profit ... large US IT conglomerate to provide HR outsourcing services in ... as an exclusive partner and will act as a talent ... will deploy over 120 personnel across 3 locations in India ... statement. , "This is a significant win for us and ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 Dr. John ... Therapeutic Periodontal Treatment to their Miami practice. Routinely ... Gallardo and Dr. Lamas are one of the ... ‘total health’ approach for diagnosing and treating periodontal disease. ... the most under-diagnosed and under-treated diseases in the world. ...
(Date:9/19/2014)... Dennis Thompson HealthDay Reporter ... President Barack Obama escalated the fight against antibiotic-resistant bacteria ... national strategy to deal with the threat. ... cabinet-level task force charged with crafting a national action ... ordinary and previously treatable bacteria that have become resistant ...
(Date:9/19/2014)... Chino Hills, CA (PRWEB) September 19, 2014 ... the fastest-selling fitness boot camp in the country. He’s also ... mentoring thousands of clients, coaching celebrity trainers and serving as ... He knows marketing, and he says that becoming an integral ... camp’s success. , “One of the things that Fit Body ...
(Date:9/19/2014)... DC (PRWEB) September 19, 2014 Atlantic ... and the authoritative AIS’s Directory of Health Plans — ... Facts, Trends and Data: 2014-2015. The latest edition of ... are re-shaping the health care industry. , With ... plan issues — from benefit design and management strategies ...
Breaking Medicine News(10 mins):Health News:Profit By RPO Bags huge RPO contract from US-based Implementation Partner 2Health News:Gallardo & Lamas Periodontics & Implant Dentistry Therapeutic Periodontal Treatment Shown to Improve Patient’s Overall Health 2Health News:Gallardo & Lamas Periodontics & Implant Dentistry Therapeutic Periodontal Treatment Shown to Improve Patient’s Overall Health 3Health News:Obama Calls for National Plan to Fight Antibiotic Resistance 2Health News:New Post from Boot Camp Marketing Expert Bedros Keuilian Explains Importance of Becoming Part of the Community 2Health News:New Post from Boot Camp Marketing Expert Bedros Keuilian Explains Importance of Becoming Part of the Community 3Health News:New Book from Atlantic Information Provides Insights Into Trends in the Health Care Industry 2
... but along with her, her families too have to face the ... breast has taken its toll on Ellen who is finding it ... Her family could seem to do nothing to ease the pain. ... palliative care team at Dartmouth Hitchcock Medical Center. ,A doctor ...
... they get married is a waste of breath, a US ... Sydney. // ,William Smith, the vice president of the ... that a six-year study commissioned by the US Congress found ... spent on pushing sexual abstinence outside marriage had had no ...
... only getting closer for the Bush administration and therefore many ... the one cited by the American Civil Liberties Union; they ... the federally sponsored ‘Abstinence Only Sex Education’ programme. ,The ... document compiled by Dr. John Santelli, a pediatrician at the ...
... A mental fog referred to as ‘chemo brain’ that ... it deserves. // , Patients especially women have ... as short-term memory loss, an inability to concentrate, difficulty ... that they had lost their mental edge. Once brushing ...
... found a breakthrough method of blood test to diagnose Parkinson ... blood much before the symptoms arrive. The test is done ... Institute and Melbourne University specialists. ,They have also ... application as it can screen many types of PD and ...
... interfere with the therapeutic effects of chemotherapy agents, ... use of antioxidants during chemotherapy. In fact, they ... the patient’s ability to tolerate treatment. This conclusion ... the use of antioxidant supplements during treatment. Until ...
Cached Medicine News:Health News:The Pain Relieved With the Help of Palliative Workers 2Health News:Chemo Brain- Nothing Forgettable About It 2Health News:Chemo Brain- Nothing Forgettable About It 3Health News:New Blood Test to Diagnose Parkinson Disease 2Health News:Antioxidants May Aid Chemotherapy Patients 2
Adjustable lid speculum angled 45 degrees with 17 mm curved solid blades and aspiration ports to remove excess fluid from around the eye during ocular procedures....
Open 11 mm blades. Dull finish. Most popular size or model....
Open 15 mm blades with lifting wings manipulation of I/A cannulas, knives, instrumentation, etc. Screwlocking mechanism. Dull finish....
Angled for temporal approach. Solid 14 mm blades. Dull finish....
Medicine Products: